Stock Market Today: Stocks Start Another Week With a Vaccine Bump
Equities rallied Monday after data showed high efficacy for an AstraZeneca (AZN) vaccine that could be more easily distributed than its peers.
The "rotation" trade returned once more after the market was greeted with COVID vaccine news for a third consecutive Monday.
The heroes today were AstraZeneca (AZN, -1.1%) and the University of Oxford, whose trial vaccine is far easier to store than other vaccines, which could make it easier to distribute across the globe. Trial data revealed an average efficacy of about 70% against COVID – lower than competitors Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA), hence AZN's down day – but adjusting dosages could get efficacy up to 90%.
The news prompted a massive spike in cyclical sectors such as financial stocks, up 1.9% as a sector, as well as energy plays such as Exxon Mobil (XOM, +6.6%) and Chevron (CVX, +6.1%) as U.S. crude oil futures climbed 1.5% to $43.06 per barrel. Stocks also enjoyed a bump after learning that President-elect Joe Biden may nominate former Fed chair Janet Yellen as his Treasury Secretary.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The Dow Jones Industrial Average jumped 1.1% to 29,591, while the Nasdaq Composite gained a more subdued 0.2% to 11,880.
Other action in the stock market today:
- The small-cap Russell 2000 closed at another record high, up 1.9% to 1,818.
- The S&P 500 improved by 0.6% to S&P 500.
- Gold futures dropped 1.8% to settle at $1,837 per ounce.
Could 2020 Finish Like It Started?
Wall Street is increasingly warming to the idea that the market could rally into the new year.
"The impending roll-out of multiple highly effective COVID vaccines and the Fed's commitment to backstopping the economy give me confidence that stocks will trade higher into year-end and beyond," says Marc Chaikin, founder of quantitative investment research firm Chaikin Analytics. "I don’t believe that caution is in order and view sideways to downward price action as a buying opportunity.
"The broadening out of the advance to include small cap, value and cyclical stocks, should be accompanied by a robust year-end rally."
If you're looking to leverage value, you can do so either through individual stocks or diversified funds, while these small-cap stocks could make hay as well. The pros also expect further gains for so-called Biden stocks as challenges to his presidential victory thin away.
Another source of gains could come from an unlikely area of the market: consumer staples stocks.
The conventional wisdom goes that staples will be in for a difficult 2021 as vaccines dampen the COVID threat and Americans emerge from their houses. But some staples plays benefit just as much if not more from an outgoing American consumer, and a few others have additional edges on their side as we head into 2021. Read on as we look at some of the best consumer staples stocks for 2021.
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Kyle Woodley is the Editor-in-Chief of WealthUp, a site dedicated to improving the personal finances and financial literacy of people of all ages. He also writes the weekly The Weekend Tea newsletter, which covers both news and analysis about spending, saving, investing, the economy and more.
Kyle was previously the Senior Investing Editor for Kiplinger.com, and the Managing Editor for InvestorPlace.com before that. His work has appeared in several outlets, including Yahoo! Finance, MSN Money, Barchart, The Globe & Mail and the Nasdaq. He also has appeared as a guest on Fox Business Network and Money Radio, among other shows and podcasts, and he has been quoted in several outlets, including MarketWatch, Vice and Univision. He is a proud graduate of The Ohio State University, where he earned a BA in journalism.
You can check out his thoughts on the markets (and more) at @KyleWoodley.
-
What's Next for MicroStrategy Stock as Bitcoin Nears $100K?
MicroStrategy stock is up more than fivefold in 2024 thanks to a furious rally in bitcoin. Here's what you need to know.
By Joey Solitro Published
-
BJ's Wholesale Pops on Membership Fee Hike, Stock Buybacks
BJ's stock is rallying Thursday after the warehouse club raised its membership fee for the first time in seven years and unveiled a big stock buyback program. Here's what you need to know.
By Joey Solitro Published
-
Why Is Warren Buffett Selling So Much Stock?
Berkshire Hathaway is dumping equities, hoarding cash and making market participants nervous.
By Dan Burrows Published
-
If You'd Put $1,000 Into Google Stock 20 Years Ago, Here's What You'd Have Today
Google parent Alphabet has been a market-beating machine for ages.
By Dan Burrows Published
-
Stock Market Today: Nasdaq Hits New High Ahead of Alphabet Earnings
The Google parent is one of several mega caps reporting earnings this week, with results due out after Tuesday's close.
By Karee Venema Published
-
Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter
Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year outlook.
By Joey Solitro Published
-
Stock Market Today: Stocks Renew Rally Ahead of Mag 7 Earnings
The Dow Jones led the major indexes higher on the strength of old-school industrial stalwart 3M.
By David Dittman Published
-
Stock Market Today: Stocks Hit Fresh Highs on Bank Earnings, Econ News
Strong corporate profits and benign economic data once again sent equities to record levels.
By Dan Burrows Published
-
Stock Market Today: Markets Slip on Hot Inflation Print, Layoff News
Economic data continues to complicate expectations for Federal Reserve rate cuts.
By Dan Burrows Published
-
Stock Market Today: Stocks Rise in Choppy Day for Markets
Moderna was the worst S&P 500 stock today after the vaccine maker slashed its R&D budget.
By Karee Venema Published